Global Pulmonary Arterial Hypertension Drugs Market 2023-2027

Global Pulmonary Arterial Hypertension Drugs Market 2023-2027

Technavio has been monitoring the pulmonary arterial hypertension drugs market and is forecast to grow by $2080.07 mn during 2022-2027, accelerating at a CAGR of 6.62% during the forecast period. Our report on the pulmonary arterial hypertension drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of PAH, the growing geriatric population, and increased risk factors for cardiovascular diseases.

Technavio's pulmonary arterial hypertension drugs market is segmented as below:

By Route of Administration

  • Oral
  • Injectable
  • Inhalation
By Action Mechanism
  • Prostacyclin analogs
  • Endothelin receptor antagonists (ERAs)
  • Phosphodiesterase (PDE) inhibitors
  • Soluble guanylate cyclase stimulators (SGCSs)
By Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increasing awareness regarding pah as one of the prime reasons driving the pulmonary arterial hypertension drugs market growth during the next few years. Also, growing technological advancements and new product launches and rising approval of pah drugs will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the pulmonary arterial hypertension drugs market covers the following areas:
  • Pulmonary arterial hypertension drugs market sizing
  • Pulmonary arterial hypertension drugs market forecast
  • Pulmonary arterial hypertension drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary arterial hypertension drugs market vendors that include Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc. Also, the pulmonary arterial hypertension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.


1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Action Mechanism
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 ($ million)
4.2 Route of Administration Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
4.3 Action Mechanism Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Action Mechanism Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Route of Administration
6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Oral - Market size and forecast 2022-2027
Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
6.4 Injectable - Market size and forecast 2022-2027
Exhibit 38: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
6.5 Inhalation - Market size and forecast 2022-2027
Exhibit 42: Chart on Inhalation - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Inhalation - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Inhalation - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Inhalation - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by Route of Administration
Exhibit 46: Market opportunity by Route of Administration ($ million)
Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Action Mechanism
7.1 Market segments
Exhibit 48: Chart on Action Mechanism - Market share 2022-2027 (%)
Exhibit 49: Data Table on Action Mechanism - Market share 2022-2027 (%)
7.2 Comparison by Action Mechanism
Exhibit 50: Chart on Comparison by Action Mechanism
Exhibit 51: Data Table on Comparison by Action Mechanism
7.3 Prostacyclin analogs - Market size and forecast 2022-2027
Exhibit 52: Chart on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
7.4 Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027
Exhibit 56: Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
7.5 Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027
Exhibit 60: Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
7.6 Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027
Exhibit 64: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Action Mechanism
Exhibit 68: Market opportunity by Action Mechanism ($ million)
Exhibit 69: Data Table on Market opportunity by Action Mechanism ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 71: Chart on Market share by geography 2022-2027 (%)
Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 UK - Market size and forecast 2022-2027
Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.9 Germany - Market size and forecast 2022-2027
Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.10 Canada - Market size and forecast 2022-2027
Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.11 Japan - Market size and forecast 2022-2027
Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 111: Market opportunity by geography ($ million)
Exhibit 112: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Aerami Therapeutics Holdings Inc.
Exhibit 119: Aerami Therapeutics Holdings Inc. - Overview
Exhibit 120: Aerami Therapeutics Holdings Inc. - Product / Service
Exhibit 121: Aerami Therapeutics Holdings Inc. - Key offerings
12.4 Asklepion Pharmaceuticals LLC
Exhibit 122: Asklepion Pharmaceuticals LLC - Overview
Exhibit 123: Asklepion Pharmaceuticals LLC - Product / Service
Exhibit 124: Asklepion Pharmaceuticals LLC - Key offerings
12.5 AstraZeneca Plc
Exhibit 125: AstraZeneca Plc - Overview
Exhibit 126: AstraZeneca Plc - Product / Service
Exhibit 127: AstraZeneca Plc - Key news
Exhibit 128: AstraZeneca Plc - Key offerings
12.6 Bayer AG
Exhibit 129: Bayer AG - Overview
Exhibit 130: Bayer AG - Business segments
Exhibit 131: Bayer AG - Key news
Exhibit 132: Bayer AG - Key offerings
Exhibit 133: Bayer AG - Segment focus
12.7 Daiichi Sankyo Co. Ltd.
Exhibit 134: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 135: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 136: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 137: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 138: Daiichi Sankyo Co. Ltd. - Segment focus
12.8 Eiger BioPharmaceuticals Inc.
Exhibit 139: Eiger BioPharmaceuticals Inc. - Overview
Exhibit 140: Eiger BioPharmaceuticals Inc. - Product / Service
Exhibit 141: Eiger BioPharmaceuticals Inc. - Key offerings
12.9 Gilead Sciences Inc.
Exhibit 142: Gilead Sciences Inc. - Overview
Exhibit 143: Gilead Sciences Inc. - Product / Service
Exhibit 144: Gilead Sciences Inc. - Key news
Exhibit 145: Gilead Sciences Inc. - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 146: GlaxoSmithKline Plc - Overview
Exhibit 147: GlaxoSmithKline Plc - Business segments
Exhibit 148: GlaxoSmithKline Plc - Key news
Exhibit 149: GlaxoSmithKline Plc - Key offerings
Exhibit 150: GlaxoSmithKline Plc - Segment focus
12.11 Johnson and Johnson Services Inc.
Exhibit 151: Johnson and Johnson Services Inc. - Overview
Exhibit 152: Johnson and Johnson Services Inc. - Business segments
Exhibit 153: Johnson and Johnson Services Inc. - Key news
Exhibit 154: Johnson and Johnson Services Inc. - Key offerings
Exhibit 155: Johnson and Johnson Services Inc. - Segment focus
12.12 Lupin Ltd.
Exhibit 156: Lupin Ltd. - Overview
Exhibit 157: Lupin Ltd. - Product / Service
Exhibit 158: Lupin Ltd. - Key news
Exhibit 159: Lupin Ltd. - Key offerings
12.13 Merck and Co. Inc.
Exhibit 160: Merck and Co. Inc. - Overview
Exhibit 161: Merck and Co. Inc. - Business segments
Exhibit 162: Merck and Co. Inc. - Key news
Exhibit 163: Merck and Co. Inc. - Key offerings
Exhibit 164: Merck and Co. Inc. - Segment focus
12.14 Novartis AG
Exhibit 165: Novartis AG - Overview
Exhibit 166: Novartis AG - Business segments
Exhibit 167: Novartis AG - Key offerings
Exhibit 168: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 169: Pfizer Inc. - Overview
Exhibit 170: Pfizer Inc. - Product / Service
Exhibit 171: Pfizer Inc. - Key news
Exhibit 172: Pfizer Inc. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 United Therapeutics Corp.
Exhibit 178: United Therapeutics Corp. - Overview
Exhibit 179: United Therapeutics Corp. - Product / Service
Exhibit 180: United Therapeutics Corp. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 181: Inclusions checklist
Exhibit 182: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 183: Currency conversion rates for US$
13.4 Research methodology
Exhibit 184: Research methodology
Exhibit 185: Validation techniques employed for market sizing
Exhibit 186: Information sources
13.5 List of abbreviations
Exhibit 187: List of abbreviations
Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market by Geography
Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary - Chart on Market Segmentation by Action Mechanism
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size - Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Action Mechanism Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits23: Five forces analysis - Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition - Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration - Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral - Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Inhalation - Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Inhalation - Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Inhalation - Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Inhalation - Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Route of Administration ($ million)
Exhibits47: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits48: Chart on Action Mechanism - Market share 2022-2027 (%)
Exhibits49: Data Table on Action Mechanism - Market share 2022-2027 (%)
Exhibits50: Chart on Comparison by Action Mechanism
Exhibits51: Data Table on Comparison by Action Mechanism
Exhibits52: Chart on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits64: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
Exhibits65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
Exhibits66: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
Exhibits67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
Exhibits68: Market opportunity by Action Mechanism ($ million)
Exhibits69: Data Table on Market opportunity by Action Mechanism ($ million)
Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits71: Chart on Market share by geography 2022-2027 (%)
Exhibits72: Data Table on Market share by geography 2022-2027 (%)
Exhibits73: Chart on Geographic comparison
Exhibits74: Data Table on Geographic comparison
Exhibits75: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibits108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibits109: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibits110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
Exhibits111: Market opportunity by geography ($ million)
Exhibits112: Data Tables on Market opportunity by geography ($ million)
Exhibits113: Impact of drivers and challenges in 2022 and 2027
Exhibits114: Overview on Criticality of inputs and Factors of differentiation
Exhibits115: Overview on factors of disruption
Exhibits116: Impact of key risks on business
Exhibits117: Vendors covered
Exhibits118: Matrix on vendor position and classification
Exhibits119: Aerami Therapeutics Holdings Inc. - Overview
Exhibits120: Aerami Therapeutics Holdings Inc. - Product / Service
Exhibits121: Aerami Therapeutics Holdings Inc. - Key offerings
Exhibits122: Asklepion Pharmaceuticals LLC - Overview
Exhibits123: Asklepion Pharmaceuticals LLC - Product / Service
Exhibits124: Asklepion Pharmaceuticals LLC - Key offerings
Exhibits125: AstraZeneca Plc - Overview
Exhibits126: AstraZeneca Plc - Product / Service
Exhibits127: AstraZeneca Plc - Key news
Exhibits128: AstraZeneca Plc - Key offerings
Exhibits129: Bayer AG - Overview
Exhibits130: Bayer AG - Business segments
Exhibits131: Bayer AG - Key news
Exhibits132: Bayer AG - Key offerings
Exhibits133: Bayer AG - Segment focus
Exhibits134: Daiichi Sankyo Co. Ltd. - Overview
Exhibits135: Daiichi Sankyo Co. Ltd. - Business segments
Exhibits136: Daiichi Sankyo Co. Ltd. - Key news
Exhibits137: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibits138: Daiichi Sankyo Co. Ltd. - Segment focus
Exhibits139: Eiger BioPharmaceuticals Inc. - Overview
Exhibits140: Eiger BioPharmaceuticals Inc. - Product / Service
Exhibits141: Eiger BioPharmaceuticals Inc. - Key offerings
Exhibits142: Gilead Sciences Inc. - Overview
Exhibits143: Gilead Sciences Inc. - Product / Service
Exhibits144: Gilead Sciences Inc. - Key news
Exhibits145: Gilead Sciences Inc. - Key offerings
Exhibits146: GlaxoSmithKline Plc - Overview
Exhibits147: GlaxoSmithKline Plc - Business segments
Exhibits148: GlaxoSmithKline Plc - Key news
Exhibits149: GlaxoSmithKline Plc - Key offerings
Exhibits150: GlaxoSmithKline Plc - Segment focus
Exhibits151: Johnson and Johnson Services Inc. - Overview
Exhibits152: Johnson and Johnson Services Inc. - Business segments
Exhibits153: Johnson and Johnson Services Inc. - Key news
Exhibits154: Johnson and Johnson Services Inc. - Key offerings
Exhibits155: Johnson and Johnson Services Inc. - Segment focus
Exhibits156: Lupin Ltd. - Overview
Exhibits157: Lupin Ltd. - Product / Service
Exhibits158: Lupin Ltd. - Key news
Exhibits159: Lupin Ltd. - Key offerings
Exhibits160: Merck and Co. Inc. - Overview
Exhibits161: Merck and Co. Inc. - Business segments
Exhibits162: Merck and Co. Inc. - Key news
Exhibits163: Merck and Co. Inc. - Key offerings
Exhibits164: Merck and Co. Inc. - Segment focus
Exhibits165: Novartis AG - Overview
Exhibits166: Novartis AG - Business segments
Exhibits167: Novartis AG - Key offerings
Exhibits168: Novartis AG - Segment focus
Exhibits169: Pfizer Inc. - Overview
Exhibits170: Pfizer Inc. - Product / Service
Exhibits171: Pfizer Inc. - Key news
Exhibits172: Pfizer Inc. - Key offerings
Exhibits173: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits174: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits175: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits176: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits177: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits178: United Therapeutics Corp. - Overview
Exhibits179: United Therapeutics Corp. - Product / Service
Exhibits180: United Therapeutics Corp. - Key offerings
Exhibits181: Inclusions checklist
Exhibits182: Exclusions checklist
Exhibits183: Currency conversion rates for US$
Exhibits184: Research methodology
Exhibits185: Validation techniques employed for market sizing
Exhibits186: Information sources
Exhibits187: List of abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings